Format

Send to

Choose Destination
Cell. 2017 Feb 9;168(4):566-570. doi: 10.1016/j.cell.2017.01.031.

Translating Germline Cancer Risk into Precision Prevention.

Author information

1
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.
2
QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
3
Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: slippman@ucsd.edu.

Abstract

Study of the biology of tumors caused by germline mutations has led to recent paradigm-changing therapy and is driving precision prevention efforts, including immune oncology and early detection research. Here, we explore recent biologic advances that are redefining the spectrum of cancers linked to various hereditary predisposition syndromes and can be leveraged to improve personalized risk assessment and develop novel interventions to prevent or intercept cancer.

PMID:
28187278
DOI:
10.1016/j.cell.2017.01.031
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center